丹奥联合低分子肝素治疗进展性脑梗死疗效观察

目的观察丹奥和低分子肝素联合治疗进展性脑梗死的疗效及安全性.方法80例急性进展性脑梗死患者随机分为治疗组和对照组,每组40例.治疗组予丹奥及克赛.对照组应用丹奥.在给药前、给药后14 d,检测血小板聚集率和凝血4项.对2组患者进行神经功能缺失评分.结果用药14 d后,治疗组活化部分凝血活酶时间（APTT）较治疗前升高（P＜0.05）,对照组则无显著性差异（P＞0.05）.治疗组总有效率为89.7%,优于对照组的77.5%.用药14 d后,治疗组神经功能缺失评分较对照组改善（P＜0.05）.结论丹奥和克赛联合治疗进展性脑梗死临床疗效更佳.

Effects of Sodium Ozagrel and Low Molecular Heparin on Progressive Cerebral Infraction

ObjectiveTo observe the combined effect and safety of Sodium Ozagrel and Low Molecular Heparin in the treatment of progressive cerebral infraction.Methods80 patients with progressive cerebral infraction were divided into experiment group and control group with 40 patients in each group. Sodium Ozagrel and Clexane both were used in the experimental group, but only Sodium Ozagrel was used in the control group. Platelet packing fraction and 4 items of blood clotting were examined before and 14 d after treatment. Neurofunctional defect was evaluated at the same time in the 2 groups.ResultsPlatelet packing fractions were significantly different when examined before treatment and 14 d after treatment both in 2 groups (P<0.05), but no difference between the 2 groups. The value of APTT 14 d after treatment in the experimental group was significantly increased (P<0.05), while this was not observed in the control group. Total effective power in experimental group was 89.7%, which was much higher than that in control group (77.5%). Neurofunctional defect evaluation in experimental group was significantly improved after treatment(P<0.05) compared with that in control. ConclusionSodium Ozagrel combined with Clexane is more effective on progressive cerebral infraction.